This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, C.-R. Articles by Rapoport, B. Search for Related Content PubMed PubMed Citation Articles by Chen, C.-R. Articles by Rapoport, B.

Suppression of Thyrotropin Receptor Constitutive Activity by a Monoclonal Antibody with Inverse Agonist Activity

Autoimmune Disease Unit, Cedars-Sinai Research Institute and University of California, Los Angeles, School of Medicine, Los Angeles, California 90048

Address all correspondence and requests for reprints to: Basil Rapoport, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Suite B-131, Los Angeles, California 90048. E-mail: rapoportb{at}cshs.org.

TSH binding to the TSH receptor (TSHR) induces thyrocyte growth and proliferation primarily by activating the adenylyl cyclase signaling pathway. Relative to the other glycoprotein hormone receptors, the TSHR has considerable ligand-independent (constitutive) activity. We describe a TSHR monoclonal antibody (CS-17) with the previously unrecognized property of being an inverse agonist for TSHR constitutive activity. This property is retained, even when constitutive activity is extremely high consequent to diverse TSHR extracellular region mutations. A similar effect on an activating mutation at the base of the sixth transmembrane helix (not accessible to direct CS-17 contact) indicates that CS-17 is acting allosterically. Administered to mice in vivo, CS-17 reduces serum T₄ levels. The CS-17 epitope is conformational and a significant portion lies in the C-terminal region of the TSHR leucine-rich domain (residues 260–289). By interacting with the large TSHR extracellular domain, CS-17 is, to our knowledge, the first antibody reported to be an inverse agonist for a member of the G protein receptor superfamily. After humanization of its murine constant region, CS-17 has the potential to be an adjunctive therapeutic agent in athyreotic patients with residual well-differentiated thyroid carcinoma as well as pending definitive treatment in some selected hyperthyroidism states.

This article has been cited by other articles:

				C.-R. Chen, S. M. McLachlan, and B. Rapoport A Monoclonal Antibody with Thyrotropin (TSH) Receptor Inverse Agonist and TSH Antagonist Activities Binds to the Receptor Hinge Region as Well as to the Leucine-Rich Domain Endocrinology, July 1, 2009; 150(7): 3401 - 3408. [Abstract] [Full Text] [PDF]

				G. Kleinau and G. Krause Thyrotropin and Homologous Glycoprotein Hormone Receptors: Structural and Functional Aspects of Extracellular Signaling Mechanisms Endocr. Rev., April 1, 2009; 30(2): 133 - 151. [Abstract] [Full Text] [PDF]

				Y. Mizutori, C.-R. Chen, F. Latrofa, S. M. McLachlan, and B. Rapoport Evidence that Shed Thyrotropin Receptor A Subunits Drive Affinity Maturation of Autoantibodies Causing Graves' Disease J. Clin. Endocrinol. Metab., March 1, 2009; 94(3): 927 - 935. [Abstract] [Full Text] [PDF]

				S. A. Morshed, R. Latif, and T. F. Davies Characterization of Thyrotropin Receptor Antibody-Induced Signaling Cascades Endocrinology, January 1, 2009; 150(1): 519 - 529. [Abstract] [Full Text] [PDF]

				C.-R. Chen, S. M. McLachlan, and B. Rapoport Identification of Key Amino Acid Residues in a Thyrotropin Receptor Monoclonal Antibody Epitope Provides Insight into Its Inverse Agonist and Antagonist Properties Endocrinology, July 1, 2008; 149(7): 3427 - 3434. [Abstract] [Full Text] [PDF]

				Y. Mizutori, C.-R. Chen, S. M. McLachlan, and B. Rapoport The Thyrotropin Receptor Hinge Region Is Not Simply a Scaffold for the Leucine-Rich Domain but Contributes to Ligand Binding and Signal Transduction Mol. Endocrinol., May 1, 2008; 22(5): 1171 - 1182. [Abstract] [Full Text] [PDF]

				X. Feng, T. Muller, D. Mizrachi, F. Fanelli, and D. L. Segaloff An Intracellular Loop (IL2) Residue Confers Different Basal Constitutive Activities to the Human Lutropin Receptor and Human Thyrotropin Receptor through Structural Communication between IL2 and Helix 6, via Helix 3 Endocrinology, April 1, 2008; 149(4): 1705 - 1717. [Abstract] [Full Text] [PDF]